A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer-Reference-Cited by-同舟云学术

A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer

Published:2016-03-19 Issue:5 Volume:77 Page:949-956
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kontopodis E.,Kotsakis A.,Kentepozidis N.,Syrigos K.,Ziras N.,Moutsos M.,Filippa G.,Mala A.,Vamvakas L.,Mavroudis D.,Georgoulias V.,Agelaki S.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-016-2997-7.pdf

Reference30 articles.

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249. doi: 10.3322/caac.20006

2. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics, 2000. CA Cancer J Clin 50(1):7–33

3. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22(2):330–353

4. Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2011) 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29(28):3825–3831. doi: 10.1200/JCO.2010.34.2774

5. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355(24):2542–2550. doi: 10.1056/NEJMoa061884

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans;Cell Death Discovery;2024-05-09

2. Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence;Health Science Reports;2023-11

3. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

4. Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells;Molecular and Cellular Biochemistry;2022-10-27

5. Deubiquitinase USP5 promotes non-small cell lung cancer cell proliferation by stabilizing cyclin D1;Translational Lung Cancer Research;2021-10